RESEARCH NEWS: CALR DESCRIBED AS IMMUNOTHERAPY TARGET

  • MPNRF | April 28, 2021

    In an abstract submission to the academic journal Leukemia, Hans Hasselbach and colleagues describe CALR as a good target for development of an immunotherapy treatment for MPN. This is following up on the 2013 discovery of the CALR mutation, which accounts for the majority of JAK2 negative MPN patients. 

    Click here to read the abstract submitted for full publication at a later date.

    Click here to read about the initial CALR discovery.